Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
                
Learn More
Learn More
Tocris Bioscience™ PF CBP1
                    Click to view available options
                
                
                    
                            
                                Quantity:
                            
                        
                        
                            
                                10 mg
                            
                        
                            
                                50 mg
                            
                        
                    Description
Selective CBP/p300 bromodomain inhibitor (IC50 values are 125 and 363 nM, respectively). Exhibits >100-fold selectivity for CBP over BRD4. Also exhibits selectivity over a panel of other bromodomains. Reduces LPS-induced IL-1β, IL-6 and IFN-β expression in macrophages in vitro. Also downregulates RGS4 expression in primary cortical neurons in vitro. 
                        
                        
                        
                        
                        
                        
                        
                        
                        
                    
                
                
                    
                
                
                
            Negative Control also available.
Specifications
Specifications
| Chemical Name or Material | 5-(Dimethyl-1,2-oxazol-4-yl)-1-[2-(morpholin-4-yl)ethyl]-2-[2-(4-propoxyphenyl)ethyl]-1H-1,3-benzodiazole | 
| CAS | 1962928-21-7 | 
| Quantity | 10 mg | 
| Target | Bromodomain Inhibitors | 
| Molecular Formula | C29H36N4O3 | 
| Formula Weight | 488.62 | 
| Purity | >98% | 
                    Product Content Correction
                
                Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
			
            Spot an opportunity for improvement?Share a Content Correction